Implementing Stimulating Innovation in the Management of Polypharmacy & Adherence through the Years (Q4302145)
Jump to navigation
Jump to search
Project Q4302145 in United Kingdom
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Implementing Stimulating Innovation in the Management of Polypharmacy & Adherence through the Years |
Project Q4302145 in United Kingdom |
Statements
2,992,570.6 Euro
0 references
3,520,671.3 Euro
0 references
85.0 percent
0 references
30 September 2019
0 references
31 March 2023
0 references
Scottish Government/NHS Scotland
0 references
Q4393156 (Deleted Item)
0 references
55°57'13.14"N, 3°11'2.04"W
0 references
Polypharmacy describes the concomitant use of multiple medicines and represents growing global challenge, which is attributable to aging populations with increasing prevalence of multi-morbidity. Polypharmacy has substantial economic impact in service demand and hospitalisation as well as detrimental impact on patients’ quality of life. The SIMPATHY EU funded project has six key recommendations to implement programmes to address this patient safety challenge which globally cost $18bn, with an estimated 8.6 million admissions annually in the EU. By 2022, the iSIMPATHY project aims to transform the approach to optimisation of medicines in the three project jurisdictions through the delivery of medicine reviews for 15,000 patients across the three project jurisdictions: 6,000 in Scotland, 4,500 in Ireland and 4,500 in Northern Ireland. It will have delivered training to 120 GPs, hospital doctors and pharmacists - 40 in each jurisdiction, across 12 local areas and will have provided a significant contribution towards the embedding of a single approach for polypharmacy management as well as firmly establishing the value of cross-border working in this field. (English)
0 references